KIA
OREX

Kopp Investment Advisors’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Kopp Investment Advisors’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-11,555
Closed -$708K – 90
2013
Q3 		$708K Sell
11,555
-9,820
-46% -$665K 0.26% 77
2013
Q2 		$1.25M Buy
+21,375
New +$1.31M 0.49% 41

Other funds holding OREX

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Kopp Investment Advisors's OREX Position: Q4 2013 in Review

Kopp Investment Advisors sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2013, closing a stake of 11,555 shares — an estimated $708K sold.

Kopp Investment Advisors first reported a position in OREX in Q2 2013 and held it in 2 quarters. The position peaked at $1.25M in Q2 2013. 124 funds tracked by Wall St. Rank hold OREX as of Q4 2013.

  • Kopp Investment Advisors reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2013 after selling out during the quarter.
  • Kopp Investment Advisors sold 11,555 Orexigen Therapeutics, Inc. shares in Q4 2013, an estimated $708K.
  • Kopp Investment Advisors first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 2 quarters.
  • Kopp Investment Advisors's Orexigen Therapeutics, Inc. position peaked at $1.25M in Q2 2013.
  • 124 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2013.

Based on Kopp Investment Advisors's 13F filing for Q4 2013, filed 21 Jan 2014.